• Nuvectis issued a correction to its release, changing only the title.
• Corrected title states ciprocopan (NXP100) won China marketing clearance for PNH patients not previously treated with complement inhibitors.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nuvectis Pharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607230900PRIMZONEFULLFEED9767077) on July 23, 2026, and is solely responsible for the information contained therein.